Wire · opportunities
$10B M&A Deal Pays Off With GSK's First Lung Cancer Drug Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
GSK's $10.6bn acquisition of Nuvalent has delivered its first FDA approval: Jideytro (zidesamtinib), a ROS1 inhibitor for advanced non-small cell lung cancer, approved ahead of schedule. The drug addresses an estimated 50,000 annual diagnoses of ROS1-positive NSCLC worldwide.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building in ROS1-positive NSCLC diagnostics, companion testing, or patient support, GSK just proved there's a buyer for this rare-mutation market and validated the 50,000-patient addressable base. Your exit price just got a comparable.
◆ Coverage
1 source · 22 Jul 2026
◆ Related on Wire
◆ Topics